TLRY vs USNA
Tilray Brands, Inc. and Usana Health Sciences Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | TLRY | USNA |
|---|---|---|
| Revenue | $915.5M | $925.3M |
| Net income | $-121.4M | $10.8M |
| Gross margin | 28.4% | 78.3% |
| Net margin | −11.5% | 1.2% |
| Return on equity | −7.8% | 2.0% |
| Diluted EPS | −$1.09 | $0.58 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | — | $8.5M |
| Equity | $1.6B | $533.1M |
| Net debt / equity | −0.13× | — |
| Current ratio | 2.21× | 2.24× |
| Revenue CAGR 5y | 12.3% | −4.0% |
| Profit CAGR 5y | — | −38.7% |
TLRY and USNA book revenue within 15% of each other, and TLRY closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Revenue by year
10 years side by side
| Fiscal year | TLRY | USNA |
|---|---|---|
| FY2025 | $915.5M | $925.3M |
| FY2024 | $821.3M | $854.5M |
| FY2023 | $788.9M | $921.0M |
| FY2022 | $627.1M | $998.6M |
| FY2021 | $628.4M | $1.2B |
| FY2020 | $513.1M | $1.1B |
| FY2019 | $405.3M | $1.1B |
| FY2018 | $179.3M | $1.2B |
| FY2017 | $20.5M | $1.0B |
| FY2016 | $12.6M | $1.0B |
Net income by year
Bottom line
| Fiscal year | TLRY | USNA |
|---|---|---|
| FY2025 | $-121.4M | $10.8M |
| FY2024 | $-2.2B | $42.0M |
| FY2023 | $-245.0M | $63.8M |
| FY2022 | $-1.5B | $69.3M |
| FY2021 | $-476.8M | $116.5M |
| FY2020 | $-367.4M | $124.7M |
| FY2019 | $-102.5M | $100.5M |
| FY2018 | $-25.0M | $126.2M |
| FY2017 | $-7.8M | $62.5M |
| FY2016 | $-7.9M | $100.0M |
More in this industry